Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald Batist

Showing results (31-40 of 165) with videos related to

Pageof 17
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 7, 2002
The nonapoptotic pathway mediating thymidine kinase/ganciclovir toxicity is reduced by signal from adenovirus type 5 early region 4Maha Katabi, Shala Yuan, Helen Chan, et al.
Cancer Chemotherapy and Pharmacology|November 27, 2009
Putative chemopreventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapiesLiangao Hu, Weimin Miao, Martin Loignon, et al.
Chemical Biology & Drug Design|May 22, 2010
Identification and characterization of novel Nrf2 inducers designed to target the intervening region of Keap1Jian H Wu, Weimin Miao, Liang G Hu, et al.
Cell Cycle (Georgetown, Tex.)|January 5, 2010
The EphB2 tumor suppressor induces autophagic cell death via concomitant activation of the ERK1/2 and PI3K pathwaysMustapha Kandouz, Khadidja Haidara, Jing Zhao, et al.
Molecular Pharmacology|March 20, 2003
Unexpected induction of the human connexin 43 promoter by the ras signaling pathway is mediated by a novel putative promoter sequenceGeorge D Carystinos, Mustapha Kandouz, Moulay A Alaoui-Jamali, et al.
Current Oncology (Toronto, Ont.)|October 25, 2024
Real-World Outcomes of Incurable Cancer Patients Treated with Unlisted Anticancer Treatments in an Academic Center in Quebec, CanadaAdam Miller, Francois Panet, Victoria Korsos, et al.
JMIR Research Protocols|March 26, 2025
Feasibility, Acceptability, and Potential Effects of a Digital Oral Anticancer Agent Intervention: Protocol for a Pilot Randomized Controlled TrialSaima Ahmed, Christine Maheu, Walter Gotlieb, et al.
Patient Education and Counseling|October 27, 2009
The impact of a multimedia informational intervention on psychosocial adjustment among individuals with newly diagnosed breast or prostate cancer: a feasibility studyCarmen G Loiselle, Linda Edgar, Gerald Batist, et al.
Expert Review of Anticancer Therapy|August 1, 2012
New frontiers in therapeutic resistance in cancerAndrea Sartore-Bianchi, Mauro Delorenzi, Thérèse Gagnon-Kugler, et al.
Anti-Cancer Drugs|May 17, 2006
Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysisGerald Batist, Lyndsay Harris, Nozar Azarnia, et al.
Pageof 17

Showing results (31-40 of 165) with videos related to

Sort By:
Pageof 17
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 7, 2002
The nonapoptotic pathway mediating thymidine kinase/ganciclovir toxicity is reduced by signal from adenovirus type 5 early region 4Maha Katabi, Shala Yuan, Helen Chan, et al.
Cancer Chemotherapy and Pharmacology|November 27, 2009
Putative chemopreventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapiesLiangao Hu, Weimin Miao, Martin Loignon, et al.
Chemical Biology & Drug Design|May 22, 2010
Identification and characterization of novel Nrf2 inducers designed to target the intervening region of Keap1Jian H Wu, Weimin Miao, Liang G Hu, et al.
Cell Cycle (Georgetown, Tex.)|January 5, 2010
The EphB2 tumor suppressor induces autophagic cell death via concomitant activation of the ERK1/2 and PI3K pathwaysMustapha Kandouz, Khadidja Haidara, Jing Zhao, et al.
Molecular Pharmacology|March 20, 2003
Unexpected induction of the human connexin 43 promoter by the ras signaling pathway is mediated by a novel putative promoter sequenceGeorge D Carystinos, Mustapha Kandouz, Moulay A Alaoui-Jamali, et al.
Current Oncology (Toronto, Ont.)|October 25, 2024
Real-World Outcomes of Incurable Cancer Patients Treated with Unlisted Anticancer Treatments in an Academic Center in Quebec, CanadaAdam Miller, Francois Panet, Victoria Korsos, et al.
JMIR Research Protocols|March 26, 2025
Feasibility, Acceptability, and Potential Effects of a Digital Oral Anticancer Agent Intervention: Protocol for a Pilot Randomized Controlled TrialSaima Ahmed, Christine Maheu, Walter Gotlieb, et al.
Patient Education and Counseling|October 27, 2009
The impact of a multimedia informational intervention on psychosocial adjustment among individuals with newly diagnosed breast or prostate cancer: a feasibility studyCarmen G Loiselle, Linda Edgar, Gerald Batist, et al.
Expert Review of Anticancer Therapy|August 1, 2012
New frontiers in therapeutic resistance in cancerAndrea Sartore-Bianchi, Mauro Delorenzi, Thérèse Gagnon-Kugler, et al.
Anti-Cancer Drugs|May 17, 2006
Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysisGerald Batist, Lyndsay Harris, Nozar Azarnia, et al.
Pageof 17